Clear cell endometrial carcinoma and the TCGA classification-Reference-Cited by-同舟云学术

Clear cell endometrial carcinoma and the TCGA classification

Published:2019-11-13 Issue:2 Volume:76 Page:336-338
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Travaglino Antonio¹^ORCID,Raffone Antonio²^ORCID,Mascolo Massimo¹,Guida Maurizio²,Insabato Luigi¹,Zannoni Gian F³,Zullo Fulvio²

Affiliation:

1. Anatomic Pathology Unit Department of Advanced Biomedical Sciences School of Medicine University of Naples Federico II Naples Italy

2. Gynecology and Obstetrics Unit Department of Neuroscience, Reproductive Sciences and Dentistry School of Medicine University of Naples Federico II Naples Italy

3. Pathology Unit Department of Woman and Child Health Agostino Gemelli University Polyclinic Catholic University of the Sacred Heart Rome Italy

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/his.13976

Reference8 articles.

1. Integrated genomic characterization of endometrial carcinoma

2. High-grade Endometrial Carcinomas

3. Targeted mutation analysis of endometrial clear cell carcinoma

4. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

5. Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometrium;Gynecologic Oncology;2024-11

2. New clinicopathological concept of endometrial carcinoma with integration of histological features and molecular profiles;Pathology International;2024-08-22

3. De-Escalated Adjuvant Treatment for Advanced MMR Deficient Mixed Endometrioid/Clear Cell Endometrial Carcinoma with PD-1 Inhibition Alone: A Case Report;Case Reports in Oncology;2024-08-05

4. MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy;Annals of Oncology;2024-07

5. Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial Cancer: A Review on Immunohistochemistry Staining Patterns and Clinical Implications;International Journal of Molecular Sciences;2024-01-15